Randomized controlled trial of pegylated interferon‐alfa 2a and ribavirin in treatment‐naive chronic hepatitis C genotype 6
Khoa D. Lam, Huy N. Trinh, Son T. Do, Thuan T. Nguyen, Ruel T. Garcia, Tuan Nguyen, Quang Q. Phan, Huy A. Nguyen, Khanh K. Nguyen, Long H. Nguyen, Mindie H. Nguyen – 29 October 2010 – Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known.